222 related articles for article (PubMed ID: 37420093)
41. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
Algazi AP; Esteve-Puig R; Nosrati A; Hinds B; Hobbs-Muthukumar A; Nandoskar P; Ortiz-Urda S; Chapman PB; Daud A
Pigment Cell Melanoma Res; 2018 Jan; 31(1):110-114. PubMed ID: 28921907
[TBL] [Abstract][Full Text] [Related]
42. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
43. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.
Wong DJ; Robert L; Atefi MS; Lassen A; Avarappatt G; Cerniglia M; Avramis E; Tsoi J; Foulad D; Graeber TG; Comin-Anduix B; Samatar A; Lo RS; Ribas A
Mol Cancer; 2014 Aug; 13():194. PubMed ID: 25142146
[TBL] [Abstract][Full Text] [Related]
44. Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.
Emran AA; Chinna Chowdary BR; Ahmed F; Hammerlindl H; Huefner A; Haass NK; Schuehly W; Schaider H
Cancer Med; 2019 Mar; 8(3):1186-1196. PubMed ID: 30793515
[TBL] [Abstract][Full Text] [Related]
45. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.
Garay T; Kenessey I; Molnár E; Juhász É; Réti A; László V; Rózsás A; Dobos J; Döme B; Berger W; Klepetko W; Tóvári J; Tímár J; Hegedűs B
PLoS One; 2015; 10(2):e0117021. PubMed ID: 25646931
[TBL] [Abstract][Full Text] [Related]
46. War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging.
Moschos SJ
Clin Cancer Res; 2022 Jul; 28(14):2977-2979. PubMed ID: 35587446
[TBL] [Abstract][Full Text] [Related]
47. Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.
Landras A; Reger de Moura C; Villoutreix BO; Battistella M; Sadoux A; Dumaz N; Menashi S; Fernández-Recio J; Lebbé C; Mourah S
Oncogene; 2022 Apr; 41(15):2254-2264. PubMed ID: 35217792
[TBL] [Abstract][Full Text] [Related]
48. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
Vu HL; Rosenbaum S; Capparelli C; Purwin TJ; Davies MA; Berger AC; Aplin AE
J Invest Dermatol; 2016 Feb; 136(2):453-463. PubMed ID: 26967478
[TBL] [Abstract][Full Text] [Related]
49. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
[TBL] [Abstract][Full Text] [Related]
50. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
51. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
52. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
[TBL] [Abstract][Full Text] [Related]
53. Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.
Phadke M; Remsing Rix LL; Smalley I; Bryant AT; Luo Y; Lawrence HR; Schaible BJ; Chen YA; Rix U; Smalley KSM
Mol Oncol; 2018 Jan; 12(1):74-88. PubMed ID: 29112787
[TBL] [Abstract][Full Text] [Related]
54. Targeting mutant NRAS signaling pathways in melanoma.
Vu HL; Aplin AE
Pharmacol Res; 2016 May; 107():111-116. PubMed ID: 26987942
[TBL] [Abstract][Full Text] [Related]
55. α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid.
Xia Y; Chen J; Gong C; Chen H; Sun J
Med Sci Monit; 2016 Apr; 22():1360-7. PubMed ID: 27104669
[TBL] [Abstract][Full Text] [Related]
56. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
57. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
58. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
59. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.
Vujic I; Sanlorenzo M; Esteve-Puig R; Vujic M; Kwong A; Tsumura A; Murphy R; Moy A; Posch C; Monshi B; Rappersberger K; Ortiz-Urda S
Oncotarget; 2016 Feb; 7(6):7297-306. PubMed ID: 26771141
[TBL] [Abstract][Full Text] [Related]
60. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Liu Y; Hawkins OE; Vilgelm AE; Pawlikowski JS; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
Clin Cancer Res; 2015 Dec; 21(23):5338-48. PubMed ID: 26152738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]